Results 141 to 150 of about 20,065,044 (264)

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva   +8 more
wiley   +1 more source

Biophysical investigation of the ligand-induced assembling of the human type I interferon receptor [PDF]

open access: yes, 2005
Type I interferons (IFNs) elicit antiviral, antiproliferative and immunmodulatory responses through binding to a shared receptor consisting of the transmembrane proteins ifnar1 and ifnar2.
Lamken, Peter
core  

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Regulation of metabotropic glutamate receptor subtype 7a by PDZ-domain protein PICK1 [PDF]

open access: yes, 2007
Metabotropic glutamate receptor subtype 7 (mGluR7) belongs to the family of G-protein coupled receptors. mGluR7 is widely distributed in the brain and primarily localized at presynaptic terminals, where it is thought to regulate neurotransmitter release ...
Zhang, C., Zhang, Chuansheng
core  

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

open access: yesBiotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady   +6 more
wiley   +1 more source

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab

open access: yesClinical, Cosmetic and Investigational Dermatology, 2009
Marina Papoutsaki, Antonio Costanzo, Sergio ChimentiDepartment of Dermatology, University of Rome, “Tor vergata”, Rome, ItalyAbstract: Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disease ...
Marina Papoutsaki   +2 more
doaj  

Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu   +23 more
wiley   +1 more source

Tetraspanin‐ESCRT sorting drives miR‐29b packaging into extracellular vesicles to reverse fibrosis in intrauterine adhesions

open access: yesBMEMat, EarlyView.
MiR‐29b is enriched in extracellular vesicles (EVs) via a tetraspanin transporter‐dependent endocytosis and sorting complex required for the endosomal transport (ESCRT)‐dependent pathway. These EVs target the 3′ untranslated region (3′UTR) of TGFB2, thereby inhibiting the TGF‐β/Smad3 signaling pathway and repairing endometrial damage in intrauterine ...
Lihao Chen   +10 more
wiley   +1 more source

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

open access: yesBMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang   +13 more
wiley   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

open access: yesBiotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Home - About - Disclaimer - Privacy